All News

Article

Drug Safety Differences with New Novel Therapies in RA

Jack Cush, MD Feb 14, 2023

Safety outcomes for targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs) used to treat RA were studied using data from the Anti-Rheumatic Therapies in Sweden (ARTIS) registry, showing that these newer agents are largely similar, but still have particular differences for specific infection or other adverse event risks.

Article

Older Lupus Patients Need Follow-Up After Hospital Discharge

MedPage Today Feb 13, 2023

Medicare beneficiaries 65 and older with lupus faced dramatically higher mortality when they received no follow-up care during the month after a hospital stay, researchers found.

Large-scale genome-wide association study of R A (276,020 samples in 5 ancestral grps) identified 124 loci (P < 5 × 10−8), 34 being novel. Candidate genes showed essential roles for TNIP2, TNFRSF11A, WISP1 in RA. https://t.co/jk1ePlen5l https://t.co/aSIZYJ9oky

https://go.nature.com/3XrrRd3

Metanalysis of HBV reactivation in HBsAg−/HBcAb+ RA ( 26 studies 2252 pts) Rx w/ b/tsDMARDs. Pooled HBV reactivation = 2%. Reactivation higher w/ RTX (esp if HBsAb−) RTX 9% (p .03) ABA 6% JAKi 1% IL‐6i 0% TNFi 0% Safe to use TNFi, JAKi, IL6 mAbs https://t.co/YCIISZTigX https://t.co/RmzAObr6w1

https://bit.ly/3S2iS0T

Subanalysis of DISCOVER-1 RCT w/ IL-23 inhibitor guselkumab, showed similar response in TNFi-naive (n 118) & TNFi-experienced (263) Rx w/ guselkumab Q4W (76% & 68%) or Q8W (61% & 58%), yet skin responses (PASI90) were better in TNFi-naive Rx PsA pts. https://t.co/tsKuLZw7dQ

https://bit.ly/3K3HT9Z

Join us on 3/18 and 3/19 in Dallas, Texas, or virtually for RheumNow Live! Will we see you there? https://t.co/hQOwBQtOny https://t.co/wwNF0gjpEj

https://bit.ly/40Si7M3

Without DMARDS, Shoulder Arthroplasty Increasing in Rheumatoid Arthritis The need for total shoulder arthroplasty (TSA) in rheumatoid arthritis (RA) patients appears to depend on the use of DMARDs, according to Seminars in Arthroplasty. https://t.co/iGAQaa7Ppc https://t.co/AbteC427wI

https://bit.ly/3YO2G5K

Does Methotrexate Increase Skin Cancer Risk? A report from the British Journal of Cancer has also shown an increased risk of basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) with MTX use; and more so with higher doses. https://t.co/tNNpFC6LiN https://t.co/x8Fuus2r8O

https://bit.ly/40Qozmy

Deucravacitinib - Effective in Systemic Lupus Erythematosus A Phase II, multicenter study has demonstrated the efficacy and safety of deucravacitinib, an oral, selective, allosteric inhibitor of TYK2, in adults with active SLE. https://t.co/0g2VM6TJt6 https://t.co/f6wylPc5ep

https://bit.ly/3E60eiS

Recent Cochrane review of Vit D, Calcium and OP shows no evidence to support the isolated or combined use of calcium & vit D in premenopausal women to improve BMD (hip or spine) or results in the prevention of fractures (vertebral and non‐vertebral). https://t.co/ZbXuPAJcGv https://t.co/pai4gmMKoI

https://bit.ly/3E2RLgA

Retrospective cohort study of Taiwan Health Insurance Database looked at risk of #SLE in pts w/ Hashimoto’s thyroiditis (HT). Compared 15K HTvs 31K controls. SLE was incr in HT pts (IRR 3.58; p < 0.01). Several sensitivity analyses aHR 4.35 to 5.11 https://t.co/QaWEN4Chw9 https://t.co/bD8zrCJEXY

https://bit.ly/40OtAfB

NLRP12 is a negative regulator of innate immune activation and type I interferon production. SLE PBMCs have low levels NLRP12 (inverse correl w/ IFNa & Hi Dz activity. NLRP12 knockouts or deficiency Incr autoAbs, inflammation & renal damage https://t.co/VICAqKmK9r https://t.co/MxqcNzh6BQ

https://bit.ly/3lv9oyY

New 5 Peptide Autoantibody Panel Complements RA Diagnosis Antibodies to peptides not currently used for rheumatoid arthritis (RA) diagnosis helped identify patients with untreated early disease that conventional biomarkers missed, researchers said. https://t.co/lOZvXBp7c1 https://t.co/6JVpeOyGYu

https://bit.ly/3XlkFPS

Systemic Sclerosis cohort study of 506 SSc pts with saw 5.3 with Degos-like lesions (89% in fingers). Degos lesions more assoc w/ diffuseSSc & acro-osteolysis, digital ulcers, and calcinosis (but not renal crisis, ILD, or pulmonary HTN https://t.co/eCumzZvEmO https://t.co/B41NLt4RYF

https://bit.ly/3JUD42R

Multicenter study of 80 AOSD & 60 controls used to develop AOSD criteria: - 3 pts rash - 3pts fever ≥ 39C - 2 pts pharyngitis - 2 pts arthritis - 2 pts NLR ≥ 4 - 1 pt glycosyl ferritin ≤ 20% 7 pts = Dx (sens 92.5%) vs Yamaguchi(79%), Fautrel (76%) https://t.co/UvtSABRs8s https://t.co/LzqWdyaj8h

https://bit.ly/3jPveNi

Full read, solid review of Diagnosis and management of autoimmune hepatitis from BMJ https://t.co/mc1ozL6CG8 https://t.co/xQkX7WpETv

https://bit.ly/3luAwyp

Pregnancy & RA: metanalysis of 9 studies, 12K RA pts met vs 10 million controls. RA preg have more maternal complications (C sect OR 1.55; preeclampsia OR, 1.6; preterm OR, 1.8) & neonatal probs (low gestat wt, ICU OR 1.34, & stillbirths OR, 1.99). https://t.co/1hA0zGsDtk https://t.co/awaV07GbEv

https://bit.ly/3HJV516

Join us on 3/18 and 3/19 in Dallas, Texas, or virtually for RheumNow Live! RheumNow Live is unlike any meeting you've ever attended. Here's why: -Inspired Education -The Audience Matters - A meeting designed to change your mind and practice. https://t.co/wWjsjWATdv https://t.co/Rd7O3Yhpw3

https://bit.ly/3DZOhve

Early ph II Pilot trial of 30 Systemic Sclerosis Pts using a new antifibrotic FT011 400mg vs 200mg v PBO x 12 wks showed CRISS score improved by 60% (400mg; (p=0.02 ) or 20% (200mg) at 12wks. An OL extension is planned for 9 mos @400 mg/d. https://t.co/ZU5wGXMDMC https://t.co/9kp20kfuCn

https://prn.to/3XvwnYk

β-damascone, a major aroma from rose, was shown in animal models to dendritic cell -mediated immune functions, thusly demonstrating anti-inflammatory properties https://t.co/0w2b2dflkM https://t.co/zz0l7DJSY4

https://bit.ly/3YKCeKh

Topics

All News

Drug Safety Differences with New Novel Therapies in RA

Older Lupus Patients Need Follow-Up After Hospital Discharge

Do you get our email newsletter?